<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578331</url>
  </required_header>
  <id_info>
    <org_study_id>C-05-69</org_study_id>
    <nct_id>NCT00578331</nct_id>
  </id_info>
  <brief_title>Safety Study of Olopatadine Nasal Spray</brief_title>
  <official_title>Safety Study of Olopatadine Nasal Spray</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether olopatadine nasal spray is safe and
      effective when used for up to one year by patients with perennial allergic rhinitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire</measure>
    <time_frame>day 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean Patient-Rated Relief Assessment at Day 30. The patient-rated relief assessment (PRRA) was a 4-point scale with 1=Complete Relief; 2=Moderate Relief; 3=Mild Relief; and 4=No Relief.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Number of Days of Rescue Medication Taken</measure>
    <time_frame>Month 1 through Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">890</enrollment>
  <condition>Perennial Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Olopatadine 0.6% Nasal Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 sprays each nostril twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 sprays each nostril twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olopatadine 0.6% nasal spray</intervention_name>
    <description>2 sprays each nostril twice daily</description>
    <arm_group_label>Olopatadine 0.6% Nasal Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Nasal Spray</intervention_name>
    <description>2 sprays each nostril twice daily</description>
    <arm_group_label>Placebo Nasal Spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with confirmed diagnosis of perennial allergic rhinitis who are 12 years and
             older

        Exclusion Criteria:

          -  Age 11 years and younger
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Drake</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <lastchanged_date>February 23, 2010</lastchanged_date>
  <firstreceived_date>December 19, 2007</firstreceived_date>
  <firstreceived_results_date>July 7, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Margaret Drake</name_title>
    <organization>Alcon</organization>
  </responsible_party>
  <keyword>rhinitis</keyword>
  <keyword>perennial allergic rhinitis</keyword>
  <keyword>allergic rhinitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Olopatadine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between December 2006 and January 2007 at medical offices in the United States.</recruitment_details>
      <pre_assignment_details>Patients were randomized at Visit 1 upon meeting inclusion/exclusion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Nasal Spray</title>
          <description>2 sprays each nostril twice daily</description>
        </group>
        <group group_id="P2">
          <title>Olopatadine 0.6% Nasal Spray</title>
          <description>2 sprays each nostril twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="445"/>
                <participants group_id="P2" count="445"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="320"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Nasal Spray</title>
        </group>
        <group group_id="B2">
          <title>Olopatadine 0.6% Nasal Spray</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="445"/>
                <measurement group_id="B2" value="445"/>
                <measurement group_id="B3" value="890"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="99"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="383"/>
                <measurement group_id="B2" value="388"/>
                <measurement group_id="B3" value="771"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="296"/>
                <measurement group_id="B2" value="282"/>
                <measurement group_id="B3" value="578"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="149"/>
                <measurement group_id="B2" value="163"/>
                <measurement group_id="B3" value="312"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire</title>
        <description>Mean Patient-Rated Relief Assessment at Day 30. The patient-rated relief assessment (PRRA) was a 4-point scale with 1=Complete Relief; 2=Moderate Relief; 3=Mild Relief; and 4=No Relief.</description>
        <time_frame>day 30</time_frame>
        <safety_issue>No</safety_issue>
        <population>29 patients had missing mean patient-rated relief assessment data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Nasal Spray</title>
          </group>
          <group group_id="O2">
            <title>Olopatadine 0.6% Nasal Spray</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="430"/>
                  <measurement group_id="O2" value="431"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire</title>
            <description>Mean Patient-Rated Relief Assessment at Day 30. The patient-rated relief assessment (PRRA) was a 4-point scale with 1=Complete Relief; 2=Moderate Relief; 3=Mild Relief; and 4=No Relief.</description>
            <units>Unit on PRRA scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.7" spread="0.9"/>
                  <measurement group_id="O2" value="2.5" spread="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Days of Rescue Medication Taken</title>
        <time_frame>Month 1 through Month 12</time_frame>
        <safety_issue>No</safety_issue>
        <population>12 patients had missing average use of rescue medication data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Nasal Spray</title>
          </group>
          <group group_id="O2">
            <title>Olopatadine 0.6% Nasal Spray</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="439"/>
                  <measurement group_id="O2" value="439"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Average Number of Days of Rescue Medication Taken</title>
            <units>Days</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.2" spread="22.4"/>
                  <measurement group_id="O2" value="11.8" spread="26.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Nasal Spray</title>
        </group>
        <group group_id="E2">
          <title>Olopatadine 0.6% Nasal Spray</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hip dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Joint surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="445"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="445"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="445"/>
                <counts group_id="E2" subjects_affected="309" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="62" subjects_affected="29" subjects_at_risk="445"/>
                <counts group_id="E2" events="44" subjects_affected="28" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="108" subjects_affected="73" subjects_at_risk="445"/>
                <counts group_id="E2" events="126" subjects_affected="87" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="102" subjects_affected="75" subjects_at_risk="445"/>
                <counts group_id="E2" events="97" subjects_affected="73" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="90" subjects_affected="67" subjects_at_risk="445"/>
                <counts group_id="E2" events="98" subjects_affected="72" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="72" subjects_affected="58" subjects_at_risk="445"/>
                <counts group_id="E2" events="96" subjects_affected="66" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="445"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="61" subjects_affected="49" subjects_at_risk="445"/>
                <counts group_id="E2" events="34" subjects_affected="31" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="110" subjects_affected="56" subjects_at_risk="445"/>
                <counts group_id="E2" events="123" subjects_affected="57" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" events="42" subjects_affected="23" subjects_at_risk="445"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="445"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="212" subjects_affected="126" subjects_at_risk="445"/>
                <counts group_id="E2" events="189" subjects_affected="111" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="148" subjects_affected="65" subjects_at_risk="445"/>
                <counts group_id="E2" events="97" subjects_affected="46" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" events="52" subjects_affected="38" subjects_at_risk="445"/>
                <counts group_id="E2" events="62" subjects_affected="46" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="445"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="29" subjects_affected="23" subjects_at_risk="445"/>
                <counts group_id="E2" events="32" subjects_affected="23" subjects_at_risk="445"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="445"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="445"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
